HEIDELBERG PHARMA AG
HEIDELBERG PHARMA AG
Action · DE000A11QVV0 · A11QVV (XFRA)
Aperçu Indicateurs financiers
4,38 EUR
1,39 % 0,06 EUR
Frankfurt (XETR) · Cours et graphiques actuels sur MoneyPeak
30.07.2025 15:36

Cours actuels de HEIDELBERG PHARMA AG

BourseTickerDeviseDernier échangeCoursVariation journalière
XETR: XETRA
XETRA
HPHA.DE
EUR
30.07.2025 15:36
4,38 EUR
0,06 EUR
+1,39 %

Performance

Jour Semaine Mois 3 mois 6 mois 1 an 5 ans
0,00 % -1,35 % -6,41 % 46,00 % 78,78 % 64,04 % 9,23 %

Profil de l'entreprise pour HEIDELBERG PHARMA AG Action

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for tumors; and HDP-XX for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; TAK-ATACs for oncology; and TLX250-CDx, a diagnostic antibody for imaging diagnostics of renal cancer in Phase III trials; urothelial carcinoma or bladder cancer in Phase I study; and triple-negative breast cancer in Phase II study. In addition, the company develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II/III study to treat COVID-19, as well as for the treatment of advanced cholangiocarcinoma; and LH011 for pancreatic cancer. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.

Données de l'entreprise

Nom HEIDELBERG PHARMA AG
Société Heidelberg Pharma AG
Site web https://heidelberg-pharma.com
Marché d'origine XFRA Frankfurt
WKN A11QVV
ISIN DE000A11QVV0
Type de titre Action
Secteur Healthcare
Industrie Biotechnology
PDG Prof. Andreas Pahl
Capitalisation boursière 210 Mio
Pays Allemagne
Devise EUR
Employés 0,1 T
Adresse Gregor-Mendel-Strasse 22, 68526 Ladenburg
Date d'introduction en bourse 2006-11-13

Symboles boursiers

Nom Symbole
Frankfurt HPHA.F
XETRA HPHA.DE

Autres actions

Les investisseurs qui détiennent HEIDELBERG PHARMA AG ont également les actions suivantes dans leur portefeuille :
ALIBABA GR. SP.ADR 8
ALIBABA GR. SP.ADR 8 Action
ALPHABET INC - CLASS A
ALPHABET INC - CLASS A Action
AMUNDI INDEX MSCI PACIFIC EX JAPAN SRI - IU (C)
AMUNDI INDEX MSCI PACIFIC EX JAPAN SRI - IU (C) ETF
APPLE INC
APPLE INC Action
BIONTECH SE ADR
BIONTECH SE ADR Action
CLIQ DIGITAL AG
CLIQ DIGITAL AG Action
FIVERR INTERNATIONAL LTD
FIVERR INTERNATIONAL LTD Action
FRAPORT AG
FRAPORT AG Action
MERCEDES BENZ GROUP AG
MERCEDES BENZ GROUP AG Action
MICROSOFT CORP
MICROSOFT CORP Action
NANOSPHERE HEA.SCIENCES
NANOSPHERE HEA.SCIENCES Action
NVIDIA CORP
NVIDIA CORP Action
PLUG POWER INC
PLUG POWER INC Action
XIAOMI CORP CL.B
XIAOMI CORP CL.B Action
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles. Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Mentions légales Protection des données Blog Communauté Retour d'information Changelog
Im App Store herunterladen Bei Google Play herunterladen
Tous droits réservés © LCP GmbH 2025